Given the high potency of navitoclax, we proposed that a dual BCL-xL and BCL-2 degrader could have similar or improved efficacy with reduced platelet toxicity in SCLC compared to navitoclax. The gene discussed is BCL2L1; the disease is small cell lung carcinoma.